Wall Street analyst estimates for Alterity Therapeutics Limited (ATHE): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-03-04 | $-0.03 | ||
| 2026-08-28 | $-0.05 | $-0.12 | +59.2% |
| 2026-02-25 | $-0.42 | $-0.25 | -65.9% |
| 2025-08-28 | $-0.34 | $-0.56 | +39.5% |
| 2025-08-04 | |||
| 2025-02-28 | $-0.57 | $-0.69 | +18.4% |
| 2025-02-03 | $-0.00 | ||
| 2024-08-29 | $-0.80 | $-0.07 | -1067.4% |
Valuation Ratios
| Price / Book | 2.73 |
| EV / EBITDA | -3.58 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $132396 | $201174 | $108538 | 0 | $4.3M | $5.1M | $3.9M | $4.0M | $5.4M | 0 |
| Cost of Revenue | $21328 | $21799 | $29696 | $112427 | $360026 | $364665 | $285067 | $214304 | $127523 | $113010 |
| Gross Profit | $111068 | $179375 | $78842 | -$112427 | $4.0M | $4.8M | $3.6M | $3.8M | $5.3M | -$113010 |
| Research & Development | $5.7M | $6.7M | $13.0M | $10.1M | $12.3M | $14.7M | $13.2M | $18.6M | $14.4M | $17.2M |
| Selling, General & Admin | $3.9M | $4.3M | $4.3M | $3.3M | $6.9M | $5.5M | $5.0M | $4.8M | $5.5M | $10.4M |
| Operating Expenses | $6.8M | $11.1M | $12.5M | $10.1M | $19.2M | $20.3M | $18.2M | $23.4M | $19.9M | $27.7M |
| Operating Income | -$6.9M | -$7.8M | -$12.7M | -$10.4M | -$15.2M | -$15.5M | -$14.6M | -$19.6M | -$14.6M | -$27.8M |
| EBITDA | -$6.9M | -$11.4M | -$12.8M | -$13.3M | -$15.2M | -$17.4M | -$14.6M | -$19.6M | -$14.6M | -$27.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$7.5M | -$8.3M | -$12.3M | -$10.1M | -$15.3M | -$12.8M | -$13.7M | -$19.1M | -$12.1M | -$26.3M |
| Income Tax | $660213 | -$495440 | -$376031 | -$362188 | -$3.1M | $70008 | $104459 | $46088 | $68055 | -$3.4M |
| Net Income | -$7.5M | -$8.3M | -$12.0M | -$10.1M | -$15.3M | -$12.8M | -$13.8M | -$19.1M | -$12.1M | -$22.9M |
| EPS | $-8.46 | $-9.30 | $-11.64 | $-6.48 | $-5.40 | $-3.18 | $-3.42 | $-3.12 | $-1.14 | $-1.32 |
| EPS (Diluted) | $-8.46 | $-9.30 | $-11.64 | $-6.48 | $-5.40 | $-3.18 | $-3.42 | $-3.12 | $-1.14 | $-1.32 |
| Shares Outstanding (Diluted) | $889819 | $889819 | $1.0M | $1.5M | $2.8M | $4.0M | $4.0M | $6.1M | $10.7M | $17.5M |
Price
| Price | $3.85 |
| Market Cap | $65M |
| Exchange | NASDAQ |
| Country | AU |
Related companies: ANVS · BTAI · DYAI · EVAX · GBIO · IGC · LIMN
Explore sector: Healthcare · Biotechnology
More sections of ATHE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks